Xi'an International Medical Center Co. Ltd.

8月28日，我校在江宁校区会议中心召开2025年秋季学期工作部署会暨中层干部培训班。校党委书记戴建君作专题辅导报告，校长郝海平部署秋季学期工作。全体校领导、中层干部、学术委员会委员、青年学术委员会委员、教工党支部书记、学科专业负责人、新药研发赛道负责人、高层次人才及辅导员代表参会。 戴建君作开班动员并以“第一性原理与大学管理”为题作专题辅导报告。他指出，能力本领是党员干部的成事之基、履职之要、立身之本，要破解“本领恐慌”，培养把握全局、谋划发展、破解复杂局面的战略能力，为高质量发展提供关键支撑。他从什么是第一性原理、大学管理的路径依赖、第一性原理如何重构或改革大学管理、重构或改革大学管理的挑战与愿景四个方面，结合学校事业发展的机遇、困境和难点，系统阐述如何运用第一性原理落实立德树人根本任务，践行“以学生为中心、以教师为主体”理念，开展管理体制机制、评价体系、教学模式、资源分配和人才培养创新改革，推进教育科技人才一体发展。 郝海平以“新时代中国药大的机遇与使命——如何把握不确定性中的确定性”为题作工作部署。他系统分析了学校当前面临的发展机遇和生物医药行业环境，基于时代大势与行业发展趋势，提出破局关键和中国药大何为的命题。通过对上半年工作的总结和对下半年要点的提炼，他指出各项工作面临的难点、堵点，强调要通过发现问题、提出问题、直面问题，在拔尖创新人才、学科群布局、重大科技创新、办学资源拓展、提升开放办学水平、培育重大标志性成果等方面创造性开展工作。 会上，发展规划与学科建设处、教务处、科学技术研究院、药学院、中药学院、国际医药商学院、多靶标天然药物全国重点实验室等7家单位进行交流发言，分管或联系校领导现场精准点评，指明努力方向，提出明确要求。 戴建君在总结讲话中要求全校各单位聚焦落实立德树人根本任务、加强党建工作、谋划“十五五”规划、推进有组织科研、筹备九十周年校庆和安全稳定工作等重点任务，全面完成年度工作目标，齐心协力推动学校事业高质量发展。 会议现场 来源 | 党委办公室 校长办公室 党委组织部 文字 | 王多兵 图片 | 崔嘉跃 编辑 | 周倩

HANGZHOU, China, July 18, 2022 /PRNewswire/ -- Broncus Medical (02216.HK) has completed surgeries on the first group of patients using its InterVapor®(including InterVapor Generator and InterVapor Catheter, the "InterVapor®"), after it was approved for marketing in China. This marked the official entry of InterVapor® into the clinical commercialization phase in China and is expected to benefit patients with chronic obstructive pulmonary disease ("COPD"). The surgeries were completed by teams of professionals led by Professor Long Fa of the Department of Respiratory, Shenzhen Hospital, University of Chinese Academy of Science; and Professor Ouyang Haifeng of the Department of Respiratory and Critical Care Medicine, Chest Hospital, Xi'an International Medical Center Hospital, respectively. The Company's self-developed InterVapor® was granted approval by the National Medical Products Administration of China (the "NMPA") in March 2022. This is the first NMPA-approved thermal vapor energy ablation systems in China and in the world for the treatment of COPD. InterVapor® is a minimally invasive interventional lung volume reduction product that can achieve sequential staged treatment by targeting the lung segments, thereby leading to a new era of interventional pulmonary in China. The Company has obtained an exclusive patent for the use of thermal vapor for pulmonary treatments with a state-of-the-art technology. During the course of the surgeries, InterVapor® delivered thermal vapor bronchoscopically to the targeted lung segment and transmitted energy through air convection, which overcomes the traditional obstacles of energy transmission due to the high air content in the lungs, and hence treating severely diseased lung segments. This method of treatment significantly improves the quality of life and lung function of patients and their exercise tolerance while preserving more healthy lung tissues. COPD is a common chronic respiratory disease and the world's third leading cause of death. According to Frost Sullivan, in 2021, there were approximately 226 million COPD patients worldwide, and at least 106 million of COPD patients in China, and the 5-year survival rate of advanced COPD patients is less than 20%. Currently, the treatment strategy of COPD is still based on drug treatment, which can delay the disease progression to a certain extent, but for severe and acutely severe patients, the effect of drug treatment is very limited. By comparing with the other treatment methods, InterVapor®-based treatment technology is highly innovative and represents a breakthrough, clinically proven to be effective and safe, and fills the gap for treatment of patients with severe emphysema. Currently, InterVapor® has been approved for marketing in major European countries, including the United Kingdom, Germany, Switzerland, Italy, and in Asia Pacific, 12 countries in total. The clinical data of STEP-UP trial (Sequential Segmental Treatment of Emphysema With Upper Lobe Predominance Trial) showed significant improvement in patients lung function and improved the quality of life in patients treated with Broncuchoscopic Thermal Vapor Ablation (BTVA) compared to standard treatment of a 12-month follow-up. Such treatment was included in the Guidelines of Global Initiative for Chronic Obstructive Lung Disease (GOLD). for four consecutive years from 2019 to 2022, which is recommended for patients with severe and acutely severe emphysema. In 2019, InterVapor® was awarded the "Breakthrough Device" designation by the U.S. FDA. About Broncus Broncus (02216.HK) is a pioneer in the interventional pulmonology medical device market, provides innovative lung solutions in China and globally. Founded in 2012, the Company has assembled a management team with extensive experience in product development, clinical research and commercialization, and has developed into an enterprise with a China-US dual center. Through close ties with key opinion leaders in the global respiratory interventional field and the establishment of a comprehensive relationship from innovative concepts to project development and implementation, the Company has built a respiratory interventional diagnosis and treatment product pipeline comprises of 17 products and major product candidates, and owned a diversified intellectual property portfolio of 686 patents and patent applications. In addition, the Company through clinical training and market education and with its strong brand promotion and commercialization capabilities, has sales to mainstream markets around the world such as the United States, Europe, and Australia. Company's mission is to become a transformative global leader in pulmonology treatment and set its interventional pulmonology diagnosis and treatment solutions as the gold standard. SOURCE Broncus